[
  {
    "ts": null,
    "headline": "Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs",
    "summary": "RAHWAY, N.J., June 12, 2025--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs.",
    "url": "https://finnhub.io/api/news?id=3918bd43e8877359f01f1932acf6d2971e6cfd3c9099b0a0a5b29df18748df30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749761100,
      "headline": "Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs",
      "id": 135224805,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., June 12, 2025--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs.",
      "url": "https://finnhub.io/api/news?id=3918bd43e8877359f01f1932acf6d2971e6cfd3c9099b0a0a5b29df18748df30"
    }
  },
  {
    "ts": null,
    "headline": "Merck Animal Health Receives EU Cvmp Positive Opinion For Numelvi Tablets For Dogs",
    "summary": "Merck & Co Inc: * MERCK ANIMAL HEALTH RECEIVES EU CVMP POSITIVE OPINION FORNUMELVI™ TABLETS FOR DOGS * MERCK & CO INC - EUROPEAN COMMISSION DECISION EXPECTED...",
    "url": "https://finnhub.io/api/news?id=ddbb5628a7c066a39da1e1989047ae6c8d8dbdd0cd09015cda3009561af230c8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749749000,
      "headline": "Merck Animal Health Receives EU Cvmp Positive Opinion For Numelvi Tablets For Dogs",
      "id": 135223690,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co Inc: * MERCK ANIMAL HEALTH RECEIVES EU CVMP POSITIVE OPINION FORNUMELVI™ TABLETS FOR DOGS * MERCK & CO INC - EUROPEAN COMMISSION DECISION EXPECTED...",
      "url": "https://finnhub.io/api/news?id=ddbb5628a7c066a39da1e1989047ae6c8d8dbdd0cd09015cda3009561af230c8"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=766dd38c8a77161958bbe80a90eb01d0ead4f323ab8f831652df2e763ffb3b55",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749746040,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 135239373,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=766dd38c8a77161958bbe80a90eb01d0ead4f323ab8f831652df2e763ffb3b55"
    }
  },
  {
    "ts": null,
    "headline": "Kennedy's new vaccine adviser was expert witness against Merck vaccine",
    "summary": "One of the new vaccine adviserspicked by U.S. Health Secretary Robert F. Kennedy Jr. has earnedthousands of dollars as an expert witness in litigation againstMerck’s Gardasil vaccine, court...",
    "url": "https://finnhub.io/api/news?id=3170c8365960ed7fb2a9d9ecebf949f09d6fcf4ad0a3fa89e60107e57e431b45",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749730574,
      "headline": "Kennedy's new vaccine adviser was expert witness against Merck vaccine",
      "id": 135214739,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "One of the new vaccine adviserspicked by U.S. Health Secretary Robert F. Kennedy Jr. has earnedthousands of dollars as an expert witness in litigation againstMerck’s Gardasil vaccine, court...",
      "url": "https://finnhub.io/api/news?id=3170c8365960ed7fb2a9d9ecebf949f09d6fcf4ad0a3fa89e60107e57e431b45"
    }
  },
  {
    "ts": null,
    "headline": "Exclusive-Kennedy's new vaccine adviser was expert witness against Merck vaccine",
    "summary": "One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an expert witness in litigation against Merck's Gardasil vaccine, court...",
    "url": "https://finnhub.io/api/news?id=7d343624168206b1132652c4c36fa43cfb39b78d5736bfb251d2c0070868228a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749727090,
      "headline": "Exclusive-Kennedy's new vaccine adviser was expert witness against Merck vaccine",
      "id": 135222065,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an expert witness in litigation against Merck's Gardasil vaccine, court...",
      "url": "https://finnhub.io/api/news?id=7d343624168206b1132652c4c36fa43cfb39b78d5736bfb251d2c0070868228a"
    }
  },
  {
    "ts": null,
    "headline": "Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate",
    "summary": "RAHWAY, N.J., June 12, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a single dose of V181, an investigational quadrivalent vaccine, for the prevention of dengue disease caused by any of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), regardless of prior dengue exposure. Recruitment for the trial has begun, and the fi",
    "url": "https://finnhub.io/api/news?id=5e83ba38cda622faf76e36aa8cc993297b7245ab94923b868eff69ba61b461de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749725100,
      "headline": "Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate",
      "id": 135220588,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., June 12, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a single dose of V181, an investigational quadrivalent vaccine, for the prevention of dengue disease caused by any of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), regardless of prior dengue exposure. Recruitment for the trial has begun, and the fi",
      "url": "https://finnhub.io/api/news?id=5e83ba38cda622faf76e36aa8cc993297b7245ab94923b868eff69ba61b461de"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Phase 3 trial for dengue vaccine",
    "summary": "Merck announces the start of the MOBILIZE-1 Phase 3 clinical trial, which is evaluating the safety, immunogenicity and efficacy of a single dose of V181, its tetravalent dengue vaccine candidate.The...",
    "url": "https://finnhub.io/api/news?id=02067117ec4249dd0001223a35212ea8b15cbc564b85808c31c98b74d5b7f278",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749721487,
      "headline": "Merck: Phase 3 trial for dengue vaccine",
      "id": 135212394,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces the start of the MOBILIZE-1 Phase 3 clinical trial, which is evaluating the safety, immunogenicity and efficacy of a single dose of V181, its tetravalent dengue vaccine candidate.The...",
      "url": "https://finnhub.io/api/news?id=02067117ec4249dd0001223a35212ea8b15cbc564b85808c31c98b74d5b7f278"
    }
  },
  {
    "ts": null,
    "headline": "Artisan Value Income Fund Q1 2025 Commentary",
    "summary": "Our portfolio generated a positive return in Q1 aided by strong gains by our Bond Proxy and Dividend Growth holdings.",
    "url": "https://finnhub.io/api/news?id=add3e08e5a758e88be40d8078a5027ce3ebb29cc657f3a918914604c24d57123",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749712200,
      "headline": "Artisan Value Income Fund Q1 2025 Commentary",
      "id": 135211063,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/571606663/image_571606663.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Our portfolio generated a positive return in Q1 aided by strong gains by our Bond Proxy and Dividend Growth holdings.",
      "url": "https://finnhub.io/api/news?id=add3e08e5a758e88be40d8078a5027ce3ebb29cc657f3a918914604c24d57123"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals",
    "summary": "German biotech firm BioNTechhas agreed to acquire domestic peer CureVacfor about $1.25 billion worth of BioNTech shares, it said onThursday, to boost its work on new mRNA-based cancer treatments. ...",
    "url": "https://finnhub.io/api/news?id=329da82cdfa0483c0e53e21bf60f9439f5e2d26329617188b5098383b0e8eead",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749711615,
      "headline": "BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals",
      "id": 135212493,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "German biotech firm BioNTechhas agreed to acquire domestic peer CureVacfor about $1.25 billion worth of BioNTech shares, it said onThursday, to boost its work on new mRNA-based cancer treatments. ...",
      "url": "https://finnhub.io/api/news?id=329da82cdfa0483c0e53e21bf60f9439f5e2d26329617188b5098383b0e8eead"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech to acquire CureVac in $1.25 billion all-stock deal",
    "summary": "German biotech firm BioNTechhas agreed to acquire domestic peer CureVacfor about $1.25 billion worth of BioNTech shares, it said onThursday, to boost its work on new mRNA-based cancer treatments. ...",
    "url": "https://finnhub.io/api/news?id=3154967456d72f4bbe07fd4bf3a78e079db1be5ebfeac198e9ff67aa307667ed",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749711615,
      "headline": "BioNTech to acquire CureVac in $1.25 billion all-stock deal",
      "id": 135211294,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "German biotech firm BioNTechhas agreed to acquire domestic peer CureVacfor about $1.25 billion worth of BioNTech shares, it said onThursday, to boost its work on new mRNA-based cancer treatments. ...",
      "url": "https://finnhub.io/api/news?id=3154967456d72f4bbe07fd4bf3a78e079db1be5ebfeac198e9ff67aa307667ed"
    }
  },
  {
    "ts": null,
    "headline": "Kennedy's ouster of US vaccine advisers puts pharma ties under scrutiny",
    "summary": "U.S. Health Secretary Robert F.Kennedy Jr.'s surprise ouster of a national vaccine advisoryboard, claiming it was plagued with persistent conflicts ofinterest, puts new scrutiny on the group that...",
    "url": "https://finnhub.io/api/news?id=1cab2389e4ab5ddeb4cca87fb0abec2116e7f6bc310ce9eeed737232cc70d83b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749708154,
      "headline": "Kennedy's ouster of US vaccine advisers puts pharma ties under scrutiny",
      "id": 135210547,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "U.S. Health Secretary Robert F.Kennedy Jr.'s surprise ouster of a national vaccine advisoryboard, claiming it was plagued with persistent conflicts ofinterest, puts new scrutiny on the group that...",
      "url": "https://finnhub.io/api/news?id=1cab2389e4ab5ddeb4cca87fb0abec2116e7f6bc310ce9eeed737232cc70d83b"
    }
  }
]